Staar Surgical Board Authorizes $50M Share Repurchase Program
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-26. Check what remains unresolved below before relying on it.
What does this change in the investment case for Staar Surgical Company?
Direct share repurchases of $50 million reduce STAA diluted share count and support EPS figures across upcoming reporting quarters.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factStaar Surgical announced a $50 million share buyback program authorized by its board of directors. |
| What else was confirmed? | Reported factThe equity gained 7.5% in the trailing Friday session following the announcement. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for STAA yet — this is the next research task. |
| What would change the assessment? | UnknownForm 10-Q Share Repurchase Disclosure — Initial dollar allocation deployed under the $50M authorization in upcoming SEC disclosures. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Staar Surgical announced a $50 million share buyback program authorized by its board of directors.
- · The equity gained 7.5% in the trailing Friday session following the announcement.
- · Management highlighted balance sheet strength and available free cash flow as justification for repurchasing undervalued shares.
Public research record
Research framework · page evidenceCompleted event assessment
equity supply reduction via open-market buyback execution
| Type | Claim | Scope |
|---|---|---|
| Assumption | Staar Surgical announced a $50 million share buyback program authorized by its board of directors. | 2026-09-26 |
| Interpretation | equity supply reduction via open-market buyback execution | STAA |
Countercase, invalidators, and sources
Rapid execution of the $50M repurchase stabilizes STAA above post-announcement levels.
- · Form 10-Q Share Repurchase Disclosure — Initial dollar allocation deployed under the $50M authorization in upcoming SEC disclosures.
- Why Staar Surgical Stock Soared Today · 2026-09-25
What remains unresolved
- Base path
- Company executes program opportunistically across H2 2026 to offset dilution.
- Adverse path
- Operational headwinds slow free cash flow generation, extending the repurchase timeline.
- Supportive path
- Rapid execution of the $50M repurchase stabilizes STAA above post-announcement levels.
- · Form 10-Q Share Repurchase Disclosure — Initial dollar allocation deployed under the $50M authorization in upcoming SEC disclosures.next month
Evidence
- Why Staar Surgical Stock Soared Today2026-09-25
“Staar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5% on Friday. The company's CEO cited confidence in the business, strong balance sheet, and ample free cash flow, noting that Staar is substantially undervalued.”
Supports: Staar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5%.